Cancerous Drugs

Introduction: A New Chapter in Cancer Immunotherapy Cancer treatment has changed dramatically over the past few decades, moving beyond chemotherapy and radiation to therapies that harness the body’s own immune system. Among these next-generation approaches, Lifileucel immunotherapy is being hailed as a personalized, cell-based treatment that offers hope to patients with advanced cancer – especially …

Read more

Introduction In the evolving field of oncology, hormonal therapy is an important part of breast cancer treatment. Among the latest advances is Elacestrant , an oral selective estrogen receptor degrader (SERD) that represents a significant leap forward in the management of estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer. Understanding the Elacestrant mechanism of action  is …

Read more

Introduction In the fast-paced world of cancer treatment, Imdelltra (tarlatamab-DLE) is emerging as a groundbreaking immunotherapy. Approved by the FDA for patients with extensive-stage small cell lung cancer (ES-SCLC) that has progressed after platinum-based chemotherapy, Imdelltra offers a new lifeline. However, beyond the clinical data, there is an essential operational aspect – the Imdelltra J …

Read more

Introduction Obinutuzumab, marketed as Gazyva in the United States and Gazyvaro in Europe, represents a major advancement in targeted cancer therapy. It’s a humanized monoclonal antibody designed to recognize and attack the CD20 antigen present on B lymphocytes. This mechanism makes it highly effective in treating Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL)—two common …

Read more

Introduction Pembrolizumab, marketed under the brand name Keytruda, is an advanced immunotherapy drug that has revolutionized cancer treatment. It works by helping the immune system to more effectively recognize and destroy cancer cells. Pembrolizumab has improved survival outcomes for many cancer patients, but it is extremely important to understand the side effects of pembrolizumab before …

Read more

Highlights What Is Imlunestrant? Imlunstrant , marketed under the brand name Inlurio, is an oral selective estrogen receptor degrader (SERD) developed by Eli Lilly & Company. It is a next-generation endocrine therapy specifically designed for postmenopausal women and men with ER-positive, HER2-negative breast cancer that harbors ESR1 mutations. Unlike older SERDs that require injections, Imlunstrant …

Read more

Introduction On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab-gcpt (brand name: Lynozyfic) for the treatment of adults with relapsed or refractory multiple myeloma (R/R MM) who have received at least four prior lines of therapy. This linvoseltamab FDA approval represents a major milestone in oncology, especially for …

Read more

Introduction On August 6, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dordaviprone (brand name: Modeyso), making history as the first systemic therapy for patients with diffuse midline glioma (DMG) harboring the H3 K27M mutation. This approval is a landmark moment, offering hope for children and adults battling this devastating and …

Read more

Introduction The U.S. Food and Drug Administration (FDA) granted accelerated approval to Zongertinib (brand name Hernexeos) on August 8, 2025, marking a significant milestone in lung cancer treatment. Zongertinib is approved for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations and …

Read more